Pfizer prevailed in a heated acquisition battle for obesity biotech Metsera, submitting a roughly $10 billion proposal that the startup accepted. The deal ended public disputes and litigation stemming from an earlier contest with Novo Nordisk and resolves a high‑stakes fight for an obesity drug program in a market reshaped by GLP‑1 contenders. Pfizer’s increased offer underscores the strategic value of pipeline assets in weight‑management therapeutics and signals continued big‑pharma willingness to pay premiums for differentiated obesity platforms. The outcome will reshape competitive positioning among manufacturers racing to commercialize next‑generation obesity medicines.